Published in final edited form as:

Biomaterials. 2016 November ; 108: 129–142. doi:10.1016/j.biomaterials.2016.08.041.

Generation of an *in vitro* 3D PDAC stroma rich spheroid model

Matthew J. Ware¹, Vazrik Keshishian¹, Justin J. Law¹, Jason C Ho¹, Carlos A Favela⁴, Paul Rees², Billie Smith³, Sayeeduddin Mohammad³, Rosa F. Hwang⁷, Kimal Rajapakshe⁸, Cristian Coarfa⁸, Shixia Huang⁸, Dean P. Edwards⁸, Stuart J. Corr^{1,4,5}, Biana Godin^{#,6}, and Steven A. Curley^{#,1}

¹Department of Surgery, Baylor College of Medicine, Houston, Texas, 77030, USA

²Department of Engineering, Swansea University, Swansea, United Kingdom

³Pathology and Histology Core, Baylor College of Medicine, Houston, Texas, 77030, USA

⁴Department of Systems Medicine and Bio-engineering, Houston Methodist Research Institute, Houston, Texas 77030, USA; Department of Chemistry, Rice University, Houston, TX 77005, USA

⁵Department of Bioengineering, University of Houston, Houston, TX 77204, USA

⁶Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, USA

⁷Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston Texas 77030, USA

⁸ Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas, 77030, USA.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a prominent desmoplastic/stromal reaction, which contributes to the poor clinical outcome of this disease. Therefore, greater understanding of the stroma development and tumor-stroma interactions is highly required.

Pancreatic stellate cells (PSC) are myofibroblast-like cells that located in exocrine areas of the pancreas, which as a result of inflammation produced by PDAC migrate and accumulate in the tumor mass, secreting extracellular matrix components and producing the dense PDAC stroma.

Currently, only a few orthotopic or ectopic animal tumor models, where PDAC cells are injected

Correspondence to: Steven A. Curley.

#CORRESPONDING AUTHORS: Dr. Steven Curley, Surgery/General Surgery Division, Baylor College of Medicine, One Baylor Plaza, Houston, Texas, 77030, Dr. Biana Godin, Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas, 77030, bianagodinv@gmail.com; bgodin@houstonmethodist.org, Phone: 713-4417329.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Author Contributions

The study was conceived by M.J.W., B.G., S.J.C. and S.A.C. M.W. and B.G. designed the experiments. M.W., J.L., V.K., J.C.H and C.A.F. performed the experiments. B.S. and S.M. performed histology. P.R. provided MATLAB analysis code. S.H., K.R. and C.C. performed the RPPA and provided statistics on proteomic data. The manuscript was written by M.J.W. and BG and edited by all authors before submission. R.H. provided the PSCs.

into the pancreas or subcutaneous tissue layer, or genetically engineered animals offer tumors that encompass some stromal component. Herein, we report generation of a simple 3D PDAC *in vitro* micro-tumor model without an addition of external extracellular matrix, which encompasses a rich, dense and active stromal compartment. We have achieved this *in vitro* model by incorporating PSCs into 3D PDAC cell culture using a modified hanging drop method. It is now known that PSCs are the principal source of fibrosis in the stroma and interact closely with cancer cells to create a tumor facilitatory environment that stimulates local and distant tumor growth. The 3D micro-stroma models are highly reproducible with excellent uniformity, which can be used for PDAC-stroma interaction analysis and high throughput automated drug-screening assays. Additionally, the increased expression of collagenous regions means that molecular based perfusion and cytostaticity of gemcitabine is decreased in our Pancreatic adenocarcinoma stroma spheroids (PDAC-SS) model when compared to spheroids grown without PSCs. We believe this model will allow an improved knowledge of PDAC biology and has the potential to provide an insight into pathways that may be therapeutically targeted to inhibit PSC activation, thereby inhibiting the development of fibrosis in PDAC and interrupting PSCPDAC cell interactions so as to inhibit cancer progression.

Keywords

3D tumor microenvironment; Pancreatic Cancer; stroma; human pancreatic stellate cells

1.0 Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related death in developed countries^{1,2}. Five-year survival is approximately 6% and survival beyond 12 months is unusual. Only 20% of patients are deemed suitable for attempted curative resection. Chemotherapy confers marginal benefit while the benefit of radiotherapy is debated³. Despite aggressive research, little improvement in patient survival has occurred in the last decade. In fact, the best chemotherapeutic treatments currently only prolong life by ~6-12 weeks⁴. The poor clinical outcome is attributed, at least in part, to the dense stromal reaction that arises during PDAC development and progression. In support of this notion, it has been shown that sequestration of chemotherapeutic agents such as gemcitabine can occur within the tumor stroma, effectively reducing the amount of the drug that can reach cancer cells⁵

One of the major players in the stromal compartment of PDAC are pancreatic stellate cells (PSCs). Pancreatic stellate cells are resident cells of the pancreas and are predominantly periacinar in location and comprise 4-7% of total pancreatic parenchymal cells. In healthy pancreas, PSCs remain in a quiescent state⁶. PSCs are thought to play a primary role in maintenance of normal pancreatic architecture due to their ability to produce extra-cellular matrix (ECM) proteins as well as the enzymes that regulate ECM protein levels, such as matrix metallo-proteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). During an acute episode of pancreatic injury, PSCs are activated and express α -smooth muscle *actin* (α -SMA), proliferate, migrate, and secrete excess ECM proteins that lay down a lattice for regenerating epithelial cells. As the injury resolves, activated PSCs are lost

through apoptosis⁷. MMPs secreted by the remaining PSCs degrade the excess fibrosis resulting in restitution of normal pancreatic tissue. However, during PDAC, an imbalance between ECM production and degradation results in an extensive and dense desmoplastic/fibrotic stroma produced by activated PSCs in which cancer cells are embedded⁸. Recent studies have alluded to PSCs playing an important role in promoting local growth of PDAC, facilitating regional and distant spread of PDAC cells^{9,10}, aiding PDAC immune-evasion¹¹⁻¹³, and facilitating a stem cell niche in PDAC, all of which have a major impact on the progression of PDAC and play a role in its high recurrence rate. This has meant that the interactions between PDAC cells and PSCs have become increasingly studied. However, there are currently very limited *in-vitro* options to study these complex interactions in a 3D tumor environment. The majority of research in the field of cancer cell biology and therapeutic modalities is performed on monocultures of cells in monolayers. While the importance of these studies is not to be understated, increasing evidence in the literature shows the merits of utilizing 3D *in vitro* models rather than 2D, to replicate more precisely the biophysics of the tumor and surrounding micro-environment¹⁴⁻¹⁶.

Three-dimensional tumor spheroids have been grown by numerous groups which enable more accurate representation of tumor cell behaviors in a more complex 3D setting, which rely on cell-cell interactions, pathogenesis, transport of nutrients and therapeutics, and other important factors. However, current spheroid models do not provide a good model for PDAC, as they have not yet featured the key dense stroma component found in all PDAC tumors *in vivo*. Orthotopic or ectopic animal models, where PSCs and PDAC cells are injected into the pancreas or subcutaneous tissue layer, offer tumors that encompass some stromal component usually lacking PSCs. Genetically engineered animal models, on the other hand, represent more precisely the stroma of PDAC¹⁷. However, the stroma compartment in these tumors is from an animal origin and these models are resource-intensive and time-consuming to create. Moreover, *in vivo* studies often provide only single end point measurements because visualizing the progress of the tumor and its response to therapies over multiple time points is difficult. These difficulties arise because of the inaccessibility of orthotopic tumors for microscopic methods or the animals needing to be sacrificed for histology analysis. Additionally, significant heterogeneity is seen in stromal reaction development *in vivo*¹⁸. These reasons lead to difficulty in obtaining mechanistic and time resolved data when studying tumor-stromal reactions in PDAC. It is, therefore, essential that more complex *in-vitro* cellular models that better mimic physiologic conditions within the tumor microenvironment be developed to study PDAC cell-stromal interactions for accurate predictions of drug or radiotherapy efficacy.

The importance of PDAC stroma interactions has been previously realized with the development of models incorporating the co-culture of PDAC and PSCs for a more 'organotypic' approach. For instance the use of 2D monolayer co-cultures¹⁹ and models which incorporate PDAC and PSCs embedded in type I glycosaminoglycan scaffolds and in collagen type I or Matrigel²⁰ have been developed. We believe that this is specifically the first *in-vitro* model, which uses PSCs co-cultured with PDAC cells whilst employing a simple method to obtain a collagen rich spheroid model without adding any external extracellular matrix components. The PDAC-SS are highly reproducible with excellent uniformity, which can be used for PDAC-stroma interaction analysis and high throughput

automated drug-screening assays. We used our recently described improved hanging drop technique²¹, which uses a viscosity-inducing agent, methylcellulose for co-culturing both PDAC cell lines²¹ and PSCs in various ratios for active stroma production. We believe our PDAC-SS model provides an *in-vitro* model for PDAC stroma rich tumors and will further improve understanding of the interaction of PDAC cells and stromal constituents and the initiation and progression of the stroma commonly found in PDAC.

2.0 Materials and Methods

2. 1. Materials

To prepare media for 3D PDAC-SS formation, cell media specific to the particular cell line (as described below) was supplemented with 20% methylcellulose stock solution. For preparation of methylcellulose stock solution 6 g of autoclaved methylcellulose powder (M0512, Sigma-Aldrich) were dissolved in preheated 250 mL basal medium (60°C) for 20 min. Thereafter, 250 mL of medium (room temperature) containing double the amount of FBS for the particular cell line was added to a final volume of 500 mL and the whole solution was mixed overnight at 4°C. The final stock solution was aliquoted and cleared by centrifugation (5000 rpm for 2h at room temperature). Only the clear, highly viscous supernatant was used for the spheroid formation, which was approximately 90-95% of the stock solution.

2.2. Cell lines

Five human PDAC lines, PANC-1, AsPc-1, BxPC-3, Capan-1 and MIA PaCa-2 cells were obtained from American Type Culture Collection (ATCC, USA). PANC-1 and AsPc-1 cells were maintained in DMEM (Thermo Fischer Scientific, USA) with 10% fetal bovine serum (FBS, Sigma, USA). BxPC-3 was maintained in RPMI-1640 (Thermo Fischer Scientific, USA) medium with 10% FBS, Capan-1 in IMDM medium (Thermo Fischer Scientific, USA) with L-4 mM glutamine and 20% FBS. MIA PaCa-2 was maintained in DMEM (Thermo Fischer Scientific, USA) with 10% FBS and 2.5% horse serum (Thermo Fischer Scientific, USA). 2% penicillin-streptomycin solution (Sigma, USA) was added to the media of all PDAC lines. Derivation of all PDAC cell lines are given by Table 1.

Human pancreatic stellate cells (PSCs) were isolated and prepared as previously described¹³ by Dr. R. Hwang (UT-MD Anderson Cancer Center, Houston TX) from human PDAC samples. Briefly, PSCs were prepared by the outgrowth method²². Fresh tissue was obtained from residual pancreatic adenocarcinoma specimens from patients undergoing primary surgical resection at The University of Texas M. D. Anderson Cancer Center. All human samples were obtained in accordance with the policies and practices of the Institutional Review Board of The University of Texas M. D. Anderson Cancer Center. Tumor samples were minced and seeded in six-well plates containing 15% FCS/DMEM, l-glutamine (2 mmol/L), penicillin/streptomycin, and amphotericin. Five days later, cells were able to grow out from the tissue clumps. When PSCs grew to confluence, cells were trypsinized and passaged 1:3. Cell purity was determined by immunohistochemistry for alpha-SMA, vimentin, and desmin, as well as morphology (spindle-shaped cells with cytoplasmic extensions) and positive staining with Oil Red O (lipid inclusions were visualized). Further,

PSC derived from the pancreatic tumor of a patient who had received no prior therapy before surgery were immortalized using lentiviral vector with human telomerase (hTERT) or SV40 large T antigen (TAg) through plasmids containing TAg (pHIV7-CNPO-TAg) and hTERT (pHIV7-CNPO-hTERT) as previously described in details.²³ PSCs carrying the hTERT or SV40-T were selected in 1 to 3 mg/mL G418 for 3 weeks (Invitrogen). Cells were maintained in DMEM with 10% FBS at 37°C in a humidified atmosphere of 5% CO₂.

2.3. A modified and improved hanging drop method for 3D PDAC-SS formation

Spheroids were created using a novel approach that we have previously described²¹. Briefly, the approach combined two traditionally used techniques: the hanging-drop technique and the use of methylcellulose in the medium. For spheroid generation we used 20% of the methylcellulose stock solution and 80% culture medium corresponding to final 0.24% methylcellulose. 20 µL drops of the 0.24% methylcellulose-culture medium solution containing 20,000 cells were pipetted onto the lid of 100 mm dishes and were inverted over dishes containing 10mL phosphate buffer solution. Cells were counted using the Countess Automated Cell Counter according to the manufacturer's recommendations (Invitrogen, USA). A ratio of 1:2 (PSCs : PDAC cells) were gently mixed using pipette action for PDACSS. Hanging drop cultures were incubated under standard culture conditions (5% CO₂, at 37°C) for 7 days, which allowed for adequate sedimentation time. The resultant cell aggregates were harvested by pipetting 10 mL of DMEM plus 10% FBS gently onto the lid where the hanging drop spheroids lay, which caused them to become suspended in the media. Each spheroid was gently caught by a sterile spatula and transferred to a well in a 12 well plate for treatment or imaging.

2.4 Generation of orthotopic PDAC tumors in mice

Animal studies were performed in accordance with the guidelines of the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals based on approved protocols by Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC). Orthotopic pancreatic tumors were grown in 6-7 week old athymic nude (FOXn1 nu) female mice (Harlan Sprague Dawley, USA). Under sterile conditions an incision of ~2 cm was made in the left flank to expose the pancreas. PANC-1 or Capan-1 cells (1×10^6 in 40 µL of PBS) were injected into the pancreas. The abdominal wound was closed in two layers. Tumors were allowed to grow for 5 weeks before tumors were excised. The tumor size was measured (average size of tumor was $4 \times 4 \times 3$ mm) before fixing in 4% formaldehyde for histology preparation.

2.5. Immunohistochemical evaluation

PDAC-SS were fixed in formalin, embedded in histogel™ (Thermo Scientific Richard-Allan Scientific, USA), processed in paraffin blocks and sectioned using standard techniques. PDAC-SS slides were stained with H&E, Ki67 (proliferation, mouse anti human Ki67, Bio-Rad, USA), Picro Sirius (collagen, Picrosirius red, AbCam, USA), Hypoxiainducible factor 1-alpha (HIF-1-α, hypoxia, AbCam, USA), and Cleaved PARP (anti-cleaved parp AB, Abcam, USA, apoptosis). Histology slides were imaged using Nikon Eclipse TE2000-U microscope fitted with a Nikon digital sight DS-Fi1 video camera. All slides were imaged at

a fixed 167ms exposure time to ensure accurate comparisons when quantifying the expression of various histology stains.

Quantities of immature and mature collagen in PDAC-SS were quantified using Picro Sirius stain. Picro Sirius stained histology slides were imaged using a Nikon Eclipse TE2000-U microscope fitted with a CoolSNAP HQ² color camera (PhotometricsTM). A MATLAB program was created to calculate the percentage area fraction of picro sirius negative and picro sirius positive regions (See Supplementary Data 1). A threshold was applied to the color image to identify the 'red' pixels segmented based on its RGB profile. This generated a binary image where white pixels represent the red or collagenous areas within the frame. The number of white pixels was divided by the total number of pixels in the image to give the percentage of collagenous pixels within the area. This was repeated for 10 PDAC-SS per group and for 20 frames of Capan-1 and PANC-1 tumors taken from 3 separate mice. The 20 frames were imaged from random areas of each tumor. Regions of both sparse and dense collagen were considered in all groups.

2.6. Scanning electron microscopy (SEM)

PDAC-SS were fixed by washing thrice with 0.1M sodium cacodylate buffer (CDB, Sigma, USA) followed by incubation in 2.5% glutaraldehyde (Sigma, USA) for 25 min at room temperature. Spheroids were washed thrice again in 0.1M CDB and subjected to an increasing concentration of ethanol (Thermo Fischer, USA) wash series for dehydration. The spheroids were then incubated in 1:1 t-butanol (Thermo Fischer, USA): ethanol mixture for 5 min and mounted on carbon tape upon an SEM stub. Immediately before imaging the samples were sputter coated with 50% platinum 50% palladium at a thickness of $5\pm0.2\text{nm}$ to ensure good electrical conductivity.

2.7. Light microscopy

Brightfield imaging for analysis of size distribution and shape of the micro-stroma and was captured at the desired time points using an Nikon Eclipse TE2000-U microscope fitted with a Nikon digital sight DS-Fi1 video camera.

2.8 Reverse-Phase Protein Array Assay

Reverse phase protein array (RPPA) assays were performed as described previously^{29,30} with minor modifications. Protein lysates were prepared from the cell culture samples with Tissue Protein Extraction Reagent (TPER; Pierce) supplemented with 450 mM NaCl and a cocktail of protease and phosphatase inhibitors (Roche Life Science). Protein lysates at 0.5 mg/ml of total protein were denatured in SDS sample buffer (Life Technologies) containing 2.5% 2-mercaptoethanol at 100 °C for 8 min. Protein lysates were arrayed onto nitrocellulose-coated slides (Grace Bio-labs, Bend, OR, USA) using an Aushon 2470 Arrayer (Aushon BioSystems, Billerica, MA, USA) with an array format of 960 (experimental and controls) lysates per slide with each sample spotted as technical triplicates (2,880 spots per slide). Slides were blocked for 1 h with I-Block reagent (Applied Biosystems) followed by a 15 min incubation with Re-Blot reagent (Dako) and were loaded on an automated slide stainer Autolink 48 (Dako, Carpinteria, CA, USA) for incubation with primary antibodies. . Antibody binding was detected by fluorescence with a Vectastain-ABC

Streptavidin–Biotin Complex (Vector, PK-6100) followed by incubation with the TSA-plus Biotin Amp Reagent diluted at 1:250 (Perkin Elmer, NEL749B001KT) and a 1:50 dilution of LI-COR IRDye 680 Streptavidin (Odyssey) as the detection probe. The total protein content of each spotted lysate was assessed by fluorescent staining with Sypro Ruby Protein Blot Stain for selected subsets of slides (Molecular Probes). Fluorescent-labelled slides were scanned on a GenePix AL4200 scanner, and the images were analyzed with GenePix Pro 7.0 (Molecular Devices). For normalization, raw image intensity of each spot was subtracted from that of negative controls and then divided by total protein values. Tumors with different genetic backgrounds were analyzed separately. Of the 212 validated antibodies included in the RPPA, 143 antibodies detect total protein and 69 detect specific phosphorylated states known to be markers of protein activation. . The validated antibodies represent proteins in various signaling pathways and cell functional groups including growth factor receptors, cell cycle, cell proliferation, apoptosis, EMT, stem cells, DNA damage, cell stress, autophagy, cytokines, protein translation and gene transcriptional activators and repressors. For a complete list of validated antibodies see <https://www.bcm.edu/centers/cancer-center/research/shared-resources/antibody-based-proteomics>. Significantly differentiated antibodies between experimental groups were determined using a cutoff of $P < 0.05$ (by two-sided Student's t-tests) and FC (fold change) > 1.25 (or $< 1/1.25$). Enriched pathways were determined by employing the gene set collections at the Molecular Signature Database (Broad Institute, USA) using a hyper-geometric distribution ($P < 0.05$).

2.9 Perfusion and drug efficacy analysis

For perfusion analysis, spheroids were exposed to 0.1 μ M FITC and fluorescence was tracked over time using a Nikon Eclipse TE2000-U microscope (Photometrics™). For drug efficacy analysis, spheroids were exposed to 100 μ M of gemcitabine for 24h, then fixed with 4% PFA for 1h. Spheroids were then stained with Ki67 and CIPARP for histological analysis.

Liquid Chromatography Mass spectroscopy- Mass Spectroscopy (LC-MS/MS) was performed to quantify the relative gemcitabine content with spheroids with and without PSCs. One hundred spheroids were harvested from the hanging drop and incubated with 1000 μ M of gemcitabine for 3h. They were then washed three times with PBS and spun down to form a pellet. To the cell pellets, 500 μ L of 4:1 (Methanol :water) with Internal Standard was added. The samples were then probe sonicated for 30 sec. Then the samples were centrifuged for 30 min at 15,000 rpm at 4C. After centrifugation the supernatant was transferred into a new tube and were dried in Speed Vac for 1 hour. The samples were suspended in 200 μ l of 50:50(methanol: water). The injection volume for LC-MS is 5 μ l.

LC-MS/MS method was developed for Gemcitabine using Agilent 6490 QQQ equipped with an Agilent jet stream source coupled to an Agilent 1290 Infinity UHPLC system. LC conditions: Waters Acquity UPLC BEH C18 column, 1.7 μ M (2.1* 100 mm) (Waters, Milford, MA) was used for the analysis. The mobile phase consisted of A: Water with methanol (80:20) with 10 mM ammonium acetate buffer; B: Acetonitrile with water (90:10) with 10 mM ammonium acetate buffer. The injection volume was 5 microL and flow rate was 0.2 mL/min. Gradient used: % B was increased from 5 (initial conditions) to 98% B in

12 min, kept constant at 98% B for 1 min (up to 13 min), returned to initial conditions (5% B) from 13 to 13.1 minutes and kept constant up to 15 minutes for column equilibration to the starting conditions.

The specific MRM transitions used for Gemcitabine compound and the optimized compound dependent MRM parameters, such as, collision energy, and dwell time. The nitrogen drying gas was set with flow rate of 14 l/min at temperature 200 °C. The pressure of the nitrogen nebulizing gas was set at 40 psi. The sheath gas temperature was 300 °C and the sheath gas flow was 11 l/min. The capillary voltage was set at 3500 Volt. The Nozzle voltage was 1500 Volt. The optimized high pressure RF was set as 200 Volt and the low pressure RF was set as 100 Volt.

Data acquisition and analysis: A Mass Hunter workstation (version B.06.01) was used for data acquisition. Mass Hunter Qualitative analysis (version B.06.01) and Quantitative analysis (version B.06.01) were used for data processing. The most abundant MRM transitions were selected for each analyte for relative-quantitation.

The relative gemcitabine content was normalized to the total surface area available for drug-spheroid surface contact, as the spheroids with PSCs tend to have a smaller diameter when compared to spheroids without PSCs.

Structural integrity of PANC-1 spheroids with and without PSCs was quantified using ImageJ analysis software 1.49U (National Institute of Health, USA). Histology images were transformed into binary format before measuring circularity and solidity of their structures. These parameters would give a quantitative measure of the spheroids structural integrity before and after gemcitabine exposure.

Circularity is defined as:

$$4\pi \frac{\text{area of spheroid}}{\text{perimeter of spheroid}^2} \quad (1)$$

A value of 1.0 indicates a perfect circle. As the value approaches 0.0, it indicates an increasingly elongated polygon.

Solidity is defined as:

$$\frac{\text{Area of spheroid}}{\text{convex area}} \quad (2)$$

Ki67 expression before and after 24h of gemcitabine exposure was quantified from histological color images captured using a Nikon Eclipse TE2000-U microscope fitted with a CoolSNAP HQ² color camera (PhotometricsTM). ImageJ software (National Institute of Health, USA) was used to perform an intensity per unit area measure to quantify the amount of Ki67 present within the spheroids, since Ki67 positive nuclei stain dark brown and negative remain light blue.

3.0 Results

3.1 Co-culture PDAC cells and PSCs in monolayer

We first cultured PDAC cells and PSCs in 2D monolayer. The base media for PANC-1 and PSCs is DMEM plus 10 and 15% FBS, respectively. However the base media for Capan-1 differs from PSCs (IMDM plus 20% FBS). By co-culturing PDAC and PSCs (2:1 ratio) cell lines in DMEM plus 15% FBS we established that both cell lines can be co-cultured with good viability in the same media. A 2:1 ratio of PDAC to PSCs was chosen after investigation of the effectiveness of various ratios to obtain uniform spheroids with collagenous regions. PDAC cells were labeled with CellTracker Green™ before being co-cultured with PSCs. After co-culture, we observed pockets of PDAC cells growing with a surrounding PSC component (Figure 1). This feature mimics micro-regions found in common PDAC tumor structure and this co-culture combination is a better 2D model for PDAC than PDAC cells cultured alone. The viability of PANC-1, Capan-1, PSCs when cultured separately in DMEM plus 15% FBS and 1% penicillin for 5 days was 97%, 92% and 94%, respectively, measured via the Trypan Blue assay (Data not shown).

3.2. Proteomic analysis

We utilized the reverse-phase protein assay (RPPA) to identify differentially expressed biomarker proteins when PSCs are co-cultured with PANC-1 or PANC-1 cells are co-cultured with PSCs. The antibody panel used for the RPPA included 212 proteins covering major cellular signaling pathways involved on tumorigenesis. The Student's t-test was used to identify significantly differentiated levels of total or phosphoproteins with p-value < 0.05 and fold-change > 1.25 (or < 1/1.25). In comparison to single medias (PSCs or PANC-1), PSCs co-cultured in PANC-1 resulted in 66 up regulated and 43 down-regulated proteins while PANC-1 cells co-cultured in PSCs resulted in 27 up regulated and 37 down-regulated proteins (Figure 2a, Tables S2a, S2b).

Table S2a and S2b (supplementary) show that p21 is one of the most dramatically up regulated proteins in both sets of cells when exposed to each conditioned media. It has previously been described that p21 can mediate many different cellular processes especially those contributing to cancer development and progression including the interplay with the pancreatic stroma³¹. Laminin5 is also strongly up regulated in both cell lines. Laminins are a family of extracellular matrix glycoproteins and are the major constituents of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling and metastasis. In addition to Laminin5, Snai2 (slug) was also up regulated in both cell lines. Although limited literature exists regarding its role in PDAC stroma development, the slug gene regulates the actin-bundling protein fascin that is involved in late-stage PanIN and PDAC formation in mice³². Fascin appears to promote formation of filopodia and invasive activities of PDAC cells³². Its levels in human PDAC correlate with outcomes and time to recurrence, indicating it might be a marker or therapeutic target for PDAC³².

Catenin (cadherin associated protein) and beta 1 (Ctnnb1) gene (proteins detected by RPPA) are both heavily up regulated by PSCs when cultured with PANC-1 media. These encode an

important cytoplasmic component of the classical cadherin adhesion complex that forms the adherens junction in epithelia and mediates cell-cell adhesion in many other tissues but also a key signaling molecule in the canonical Wnt signaling pathway that controls cell growth and differentiation during both normal development and tumorigenesis. Analysis of PDAC stroma in comparison to the stroma of chronic pancreatitis also demonstrates overexpression of Wnt5a in PDAC stroma³¹. It has previously been suggested that overexpression of Wnt signaling may contribute to the strong desmoplastic reaction seen in PDAC³³. The up regulation of MAPK found in this analysis corroborate results from Erkan *et al.*, 2012 who highlighted that activation of stromal cells by pancreatic cancer cells is a persisting event that involves other pathways such as mitogen-activated protein kinase (MAPK)³⁴ which may lead to the production of dense desmoplastic reaction in PDAC. Both cell lines cultured in conditioned media displayed altered expression of proteins which have previously been shown to be implicated in activated stroma such as integrin, Ax1, MMP-9, Stat1, SOCS3 and Vimentin³⁵. Gene set enrichment analysis performed using a hyper geometric method revealed that a number of pathways, such as Chiaradonna neoplastic transformation KRAS, Reactome NCAM signaling for neurite out growth and Kobayashi EGFR signaling related to activated stroma³⁵ are enriched in the co-culture signatures (Figure 2b).

3.3 Design and characterization of PDAC-SS

Brightfield microscopy revealed that PDAC-SS were smaller in diameter than their spheroid counterparts after 7 days of growth (Figure 3). However their optical density was measured to be between 25-50% higher at the same time-point. One hypothesis to describe this phenomenon is that PSCs and their production of ECM proteins, including collagen, create a tightly bound matrix on which the cancer cells grow. Furthermore, collagenous material may fill gaps between the cells to increase density of the overall tumor structure (Figure 3D). The increased density has major implications for the diffusion of drug molecules, and hence may be an important factor in PDAC drug resistance that is commonly observed in human patients.

Scanning electron micrographs (Figure 4) reveal individual cell aggregates on the surface of the spheroid tumors. However, the surface of the spheroids is very different when grown with PSCs as a dense fibrous-like bed on the surface of PDAC-SS can be observed, which much more closely resembles the surface of the orthotopic PDAC tumor from a PANC-1 nude mouse model.

3.4 Quantification of collagen content in 3D PDAC-SS

One of the most widely used methods to visualize fibrosis in histological tissue is by staining it with Picro Sirius red³⁶⁻⁴⁰. Picro Sirius red, in contrast to more traditional stains like van Gieson and trichrome, has greater selectivity and thus is superior for both staining and quantification of collagen^{40,41}. Picro Sirius red stains collagenous positive regions within the spheroid red with non-collagenous regions counterstained blue. Figure 5 (and Figure S1) shows extensive Picro Sirius positive regions in PDAC-SS. The percentage area fraction of collagenous regions within each spheroid was calculated based on picro-sirius positive and negative regions. This was also performed on tumor samples that had been

generated using PANC-1 and Capan-1 cells injected into the pancreas of nude mice and on human PDAC samples (Figure 4).

Percentage area fraction of collagen rich was quantified in capan-1 and PANC-1 spheroids due to them being the two most collagenous spheroid models. Limited increases in AsPc-1 and BxPc-3 were observed. Percentage area quantification of picro sirius positive regions in PANC-1 and Capan-1 spheroids (-PSCs) using the MATLAB program (Supplementary Data 2) yielded a 9% and 8% collagen content respectively. PANC-1 and Capan-1 *in vivo* tumors contained 37% and 24% collagen content respectively. This means the spheroids contained more than 4 times less collagen and 3 times less collagen than the *in vivo* tumors. However, PDAC-SS micro-tumors contained 25% (PANC-1) and 18% (Capan-1) collagenous material and hence more accurately represent the amount of collagen found in *in vivo* tumor tissues. Human grade 3 stage 1 and 2 displayed both sparse and dense collagen regions (24% and 18%, respectively) and human grade 1 stage 3 possessed a large amount of sparse and dense collagen (70%).

3.5 The effect of collagen in PDAC-SS on drug diffusion

Immunohistochemistry determined that the stromal regions in the PDAC-SS model consist of Collagen I and III, fibronectin and SMA. The natural arrangement of crosslinking within the fibrils found in these substances makes the fibers highly resistant to tensile forces, and capable of dissipating significant deformation energy⁴². In PDAC, collagen decreases tissue elasticity and increases interstitial pressure, resulting in reduced drug perfusion (Figure 7).

FITC fluorescent marker was used to measure the molecular perfusion (FITC MW 389g/mol, gemcitabine MW=263g/mol) through PDAC spheroids with and without PSCs (Figure 6A-C). LC-MS/MS was also performed to measure the relative gemcitabine content when spheroids with and without PSCs were incubated with 1000uM gemcitabine for 3h. This physiological chemoresistance has previously been shown to be a major contributor to the reduced efficacy of chemotherapeutics in PDAC⁴³. As shown in Figure 7, diffusion of both FITC and gemcitabine was significantly impaired in stroma rich spheroids as compared with spheroids composed of only PDAC cells. Figure 8 shows that PDAC-SS model are more structurally viable indicated by the compact nature of the spheroids and have a greater proliferation index (shown by Ki67 expression) after 24h exposure to 1000uM gemcitabine, when compared to spheroids without the PSCs/fibrotic component.

PANC1 spheroids with PSCs display a much more dense appearance and increased structural integrity after gemcitabine exposure as given by circularity and solidity measurements. Circularity and Solidity are given by equations 1 and 2 respectively and are shape descriptors used to quantify the structure of the spheroids before after gemcitabine exposure (Figure 8). However, it was also observed that PANC1 spheroids with PSCs displays comparable ki67 content when compared to PANC-1 spheroids without PSCs before and after 120h of gemcitabine exposure (Figure 9).

4.0 Discussion

A key histopathological feature of PDAC that is associated with its innate clinical and biological aggressiveness is its pronounced desmoplastic (stromal) reaction, which is now considered a potential therapeutic target in PDAC⁴⁴. Stroma production is stimulated by cancer-cell derived growth factors including transforming growth factor- β (TGF β), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF)⁴⁵. The desmoplastic reaction is composed of ECM proteins, primarily type I and III collagen, fibronectin and proteoglycans; small endothelium lined vessels; and a diverse population of cells including inflammatory cells, fibroblasts and stellate cells⁴⁶. The stroma can form up to 90% of the tumor volume, a property which is unique to pancreatic cancer^{47,48}. The response of pancreatic cancer cells to chemotherapeutic agents *in vitro* is similar to cell lines derived from other solid tumors⁴⁸. However, pancreatic cancer patients have a limited response to drugs such as paclitaxel compared to breast and prostate cancer patients, suggesting that the unique tumor microenvironment in pancreatic cancer plays a role in chemoresistance⁴⁸. Erkan *et al*⁴⁹ observed through staining pancreatic cancer tissue sections of patients for alpha smooth muscle actin (α -SMA the cytoskeletal protein marker for PSC activation) and collagen that a high activated stroma index (α -SMA/collagen) correlated with a poor prognosis. Furthermore, the extensive ECM deposition by PSCs in pancreatic cancer causes distortion and compression of tumor vasculature by fibrous tissue, which contributes to tumor hypoxia, a determinant of chemoresistance^{5,50}. Therefore, improved *in vitro* models of PDAC with active stroma, such as our PDAC-SS model, will enhance understanding of the dynamic interaction between cancer cells and stroma compartments. This is an important consideration when designing new, effective therapeutic strategies for pancreatic cancer.

Both PDAC-SS and orthotopic tumors displayed both sparse and dense collagenous areas, indicated by the dim and bright red picro sirius positive regions, respectively. PANC-1 PDAC-SS contained very dense collagen whereas Capan-1 PDAC-SS contained collagen fibers that had shrunk, most probably through histology preparation, to leave blank spaces within the tumor architecture. This feature is also seen in orthotopic tumor collagen. Tumor spheroids grown without PSCs, in contrast, displayed only sparse collagen and notably no dense collagenous areas.

Although the main focus of this work considered stroma content, immunohistochemistry analysis also showed that traditional spheroids and our PDAC-SS model possess hallmarks commonly found in PDAC (Fig S3, S4 and S5). We have explored the viability of the spheroids at time points passed 2 weeks. However, the time point at harvest was chosen particularly because it represents the time in which the spheroids are most structurally viable. Since stroma rich pancreatic tumors should grow for longer periods of times *in vivo* (~1-2 months) we will not be able to maintain our spheroids for that long due to obvious limitations of the *in vitro* cell culture. However, at 7-10 day growth time we have found that the expression of such hallmarks of cancer, which include Ki-67 and HIF-1 α is similar between the PDAC-SS and the tumors grown orthotopically in the pancreas of mice. The expression of the human monoclonal Ki-67 antibody is strictly associated with cell proliferation. Ki-67 protein is present during all active phases of the cell (G1, S, G2, and

mitotic phases) but is absent from resting cells (G0 phase), which makes it a reliable marker for determining the growth fraction of cells in a given cell population⁵¹. The fraction of Ki-67-positive tumor cells, also known as the Ki-67 labeling index, is often correlated with the clinical course of the disease⁵¹. Ki-67 has been used in combination with other biomarkers and clinicopathological predictors to predict patient survival post surgery in pancreatic cancer⁵².

PDAC-SS also expressed hypoxia-inducible factor 1 alpha, (HIF-1 α) which is a transcription factor that mediates cellular and systemic homeostatic responses to reduced O₂ availability in mammals, including angiogenesis, erythropoiesis and glycolysis. HIF-1 α is over expressed during carcinogenesis and wound healing. It is crucial for the cellular response to hypoxia and is frequently over expressed in human cancers, resulting in the activation of genes essential for cell survival. HIF-1 α regulates the survival and function in the inflammatory microenvironment directly.

Proteomic-based approaches were also used to highlight potential genes, some of which are already known to be associated with PDAC-stroma interactions and fibrosis development in PDAC and some of which are not currently known. With a recent interest in moving toward an integrative, rather than reductionist, approach to PDAC biology in the post-genomic era, proteomic pattern comparisons between 2D and 3D mono and co-cultures may lead to the discovery of numerous potential biomarkers that could be translated into diagnosis or prognosis in the clinical field.

Finally, we demonstrated that the PDAC-SS model displayed a lower molecular perfusion and a slight trend in higher proliferative index after 24h exposure of FITC fluorescent molecule and gemcitabine, respectively. Concentrations used in this manuscript are comparable to concentrations routinely used in in-vitro studies in PDAC using gemcitabine. In in-vivo scenarios, 30-60mg/kg may be injected into the mouse with a fraction of this dose arriving at the tumor. This model can act as a bridge between in vitro and in vivo as in vitro doses are used however not all cells possess a cell-drug interface which is comparable to in vivo situation.

5.0 Conclusions

It is clear that the prominent stromal/desmoplastic reaction of PDAC can no longer be dismissed as a mere epiphenomenon of carcinogenesis. Indeed, available evidence strongly indicates that this stromal reaction, and in particular the cells responsible for its production, PSCs, likely play a key role at the different stages of pancreatic cancer development and response to therapy. Therefore, all components of this reaction (stromal cells and collagenous matrix) warrant attention as potentially useful, additional therapeutic targets in this disease. In this work, we have developed an *in vitro* model of PDAC tumor that incorporates a prominent desmoplastic reaction through the incorporation of PSCs into a spheroid model. Spheroids grown with PSCs are more dense and compact and exhibit larger collagen content than spheroids grown solely with PDAC cell lines. In addition to similarities in collagen content, PDAC-SS are also very similar to orthotopic tumors in expression of KI67 and HIF-1 α . PDAC-SS are thus an important advancement in the

development of in vitro tumor models that closely resemble actual tumor microenvironments in patients. Future challenges in this field of research will be to develop experimental 3D *in vitro* models (or a range of models) that not only closely simulate the pathology, but also account for the heterogeneity and full range of cell types found in human PDAC, so as to successfully translate research findings into clinically effective therapies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

B.G. acknowledges the financial support from NIH U54CA143837 Physical Sciences and Oncology grant, NIH 1U54CA151668-01 Cancer Centre for Nanotechnology Excellence grant and 1R21HD082947. MJW, SC and SJC acknowledge the financial support from Kanzius Cancer Research Foundation. The authors would also like to acknowledge kind assistance of Kemi Cui (HMRI Advanced Cellular and Tissue Microscope Core Facility) for his help with acquiring color histological images. SH, CC and KR acknowledges the financial support from Cancer Prevention & Research Institute of Texas Proteomics & Metabolomics Core Facility Support Award (RP120092) (DPE and SH) and NCI Cancer Center Support Grant to Antibody-based Proteomics Core/Shared Resource (P30CA125123) (DPE and SH). The metabolomics core is also supported by CPRIT Core facility award RP120092-DPE is PI). The authors would also like to acknowledge the LC-MS/MS work performed by Sri Ramya Donepudi and Nagireddy Putluri in Advanced Technology Core, Baylor College of Medicine. The Advanced Technology Core is supported by the following grants: NCI/ 2P30CA125123-09 Shared Resources Metabolomics core and funds from Dan L. Duncan Cancer Center (DLDC), Baylor college of Medicine.

References

1. Jemal A, et al. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69–90. doi: 10.3322/caac.20107. [PubMed: 21296855]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63:11–30. doi:10.3322/caac.21166. [PubMed: 23335087]
3. Manton TS, Lunardi S, Al-Assar O, Masamune A, Brunner TB. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta1-integrin signaling. Cancer research. 2011; 71:3453–3458. doi:10.1158/0008-5472.can-10-1633. [PubMed: 21558392]
4. Trouilloud I, et al. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol. 2011; 35:364–374. doi:10.1016/j.clinre.2011.02.002. [PubMed: 21435966]
5. Olive KP, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324:1457–1461. doi:1171362 [pii] 10.1126/science.1171362. [PubMed: 19460966]
6. Apte MV, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut. 1998; 43:128–133. [PubMed: 9771417]
7. Tahara J, Shimizu K, Shiratori K. Engulfment of necrotic acinar cells by pancreatic stellate cells inhibits pancreatic fibrogenesis. Pancreas. 2008; 37:69–74. doi:10.1097/MPA.0b013e318160a5cb. [PubMed: 18580447]
8. Apte MV, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004; 29:179–187. [PubMed: 15367883]
9. Xu Z, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. The American journal of pathology. 2010; 177:2585–2596. doi:10.2353/ajpath.2010.090899. [PubMed: 20934972]
10. Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Frontiers in physiology. 2014; 5:52. doi:10.3389/fphys.2014.00052. [PubMed: 24592240]
11. Tang D, et al. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer.

- International journal of cancer. Journal international du cancer. 2012; 130:2337–2348. doi: 10.1002/ijc.26290. [PubMed: 21780106]
12. Ene-Obong A, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. *Gastroenterology*. 2013; 145:1121–1132. doi:10.1053/j.gastro.2013.07.025. [PubMed: 23891972]
 13. Hwang RF, et al. Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression. *Cancer research*. 2008; 68:918–926. doi:10.1158/0008-5472.CAN-07-5714. [PubMed: 18245495]
 14. Mellor HR, Ferguson DJ, Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. *British journal of cancer*. 2005; 93:302–309. doi:10.1038/sj.bjc.6602710. [PubMed: 16052217]
 15. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. *Journal of biomolecular screening*. 2004; 9:273–285. doi:10.1177/1087057104265040. [PubMed: 15191644]
 16. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. *Cancer research*. 2003; 63:5970–5977. [PubMed: 14522924]
 17. Ijichi H. Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. *World Journal of Clinical Oncology*. 2011; 2:195–202. doi:10.5306/wjco.v2.i5.195. [PubMed: 21611096]
 18. Waghray M, Yalamanchili M, di Magliano MP, Simeone DM. Deciphering the Role of Stroma in Pancreatic Cancer. *Current opinion in gastroenterology*. 2013; 29:537–543. doi:10.1097/MOG.0b013e328363affe. [PubMed: 23892539]
 19. Carapuca EF, et al. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. *The Journal of pathology*. 2016 doi:10.1002/path.4727.
 20. Coleman SJ, et al. Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. *World journal of gastroenterology*. 2014; 20:8471–8481. doi: 10.3748/wjg.v20.i26.8471. [PubMed: 25024603]
 21. Ware M, et al. Generation of homogenous 3D pancreatic cancer cell spheroids using an improved hanging drop technique. *Tissue Engineering C (under review)*. 2015
 22. Bachem MG, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. *Gastroenterology*. 2005; 128:907–921. [PubMed: 15825074]
 23. Erkan M, et al. Preoperative acute pancreatitis in periampullary tumors: implications for surgical management. *Digestion*. 2007; 75:165–171. doi:10.1159/000106799. [PubMed: 17684367]
 24. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. *International journal of cancer. Journal international du cancer*. 1975; 15:741–747. [PubMed: 1140870]
 25. Chen WH, et al. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. *In vitro*. 1982; 18:24–34. [PubMed: 7182348]
 26. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. *International journal of cancer. Journal international du cancer*. 1977; 19:128–135. [PubMed: 832918]
 27. Kyriazis AP, et al. Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. *The American journal of pathology*. 1982; 106:250–260. [PubMed: 6278935]
 28. Tan MH, et al. Characterization of a new primary human pancreatic tumor line. *Cancer investigation*. 1986; 4:15–23. [PubMed: 3754176]
 29. Holdman XB, et al. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. *Breast Cancer Res*. 2015; 17:141. doi: 10.1186/s13058-015-0649-1. [PubMed: 26581390]
 30. Welte T, et al. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. *Nat Cell Biol*. 2016; 18:632–644. doi:10.1038/ncb3355. [PubMed: 27183469]

31. Pilarsky C, et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. *Journal of cellular and molecular medicine*. 2008; 12:2823–2835. doi: 10.1111/j.1582-4934.2008.00289.x. [PubMed: 18298655]
32. Li A, et al. Fascin Is Regulated by Slug, Promotes Progression of Pancreatic Cancer in Mice, and Is Associated With Patient Outcomes. *Gastroenterology*. 2014; 146:1386–1396. e1317. doi:10.1053/j.gastro.2014.01.046. [PubMed: 24462734]
33. Pilarsky C, et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. *Journal of cellular and molecular medicine*. 2008; 12:2823–2835. doi: 10.1111/j.1582-4934.2008.00289.x. [PubMed: 18298655]
34. Erkan M, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. *Nature reviews. Gastroenterology & hepatology*. 2012; 9:454–467. doi:10.1038/nrgastro.2012.115. [PubMed: 22710569]
35. Moffitt RA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nature genetics*. 2015; 47:1168–1178. doi:10.1038/ng.3398. [PubMed: 26343385]
36. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. *The Histochemical journal*. 1979; 11:447–455. [PubMed: 91593]
37. Mito S, et al. Myocardial protection against pressure overload in mice lacking Bach1, a transcriptional repressor of heme oxygenase-1. *Hypertension*. 2008; 51:1570–1577. doi:10.1161/hypertensionaha.107.102566. [PubMed: 18426999]
38. Puchtler H, Waldrop FS, Valentine LS. Polarization microscopic studies of connective tissue stained with picro-sirius red FBA. *Beitrage zur Pathologie*. 1973; 150:174–187. [PubMed: 4129194]
39. Seeland U, et al. Interstitial remodeling in beta1-adrenergic receptor transgenic mice. *Basic research in cardiology*. 2007; 102:183–193. doi:10.1007/s00395-006-0635-y. [PubMed: 17122889]
40. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. *Basic research in cardiology*. 1994; 89:397–410. [PubMed: 7535519]
41. Whittaker P, Boughner DR, Kloner RA. Analysis of healing after myocardial infarction using polarized light microscopy. *The American journal of pathology*. 1989; 134:879–893. [PubMed: 2705508]
42. Buehler MJ. Nature designs tough collagen: explaining the nanostructure of collagen fibrils. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103:12285–12290. doi:10.1073/pnas.0603216103. [PubMed: 16895989]
43. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. *Nature reviews. Cancer*. 2004; 4:806–813. doi:10.1038/nrc1456. [PubMed: 15510161]
44. Kong X, Li L, Li Z, Xie K. Targeted Disruption of Orchestration between Stroma and Tumor Cells in Pancreatic Cancer: Molecular Basis and Therapeutic Implications. *Cytokine & growth factor reviews*. 2012; 23:343–356. doi:10.1016/j.cytogfr.2012.06.006. [PubMed: 22749856]
45. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. *Molecular cancer therapeutics*. 2007; 6:1186–1197. doi:10.1158/1535-7163.mct-06-0686. [PubMed: 17406031]
46. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J. Tumor microenvironment and progression of pancreatic cancer. *Experimental oncology*. 2010; 32:128–131. [PubMed: 21403605]
47. Neesse A, et al. Stromal biology and therapy in pancreatic cancer. *Gut*. 2011; 60:861–868. doi: 10.1136/gut.2010.226092. [PubMed: 20966025]
48. Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. *The AAPS journal*. 2010; 12:223–232. doi:10.1208/s12248-010-9181-5. [PubMed: 20198462]
49. Erkan M, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2008; 6:1155–1161. doi: 10.1016/j.cgh.2008.05.006. [PubMed: 18639493]

50. Couvelard A, et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. *Histopathology*. 2005; 46:668–676. doi:10.1111/j.1365-2559.2005.02160.x. [PubMed: 15910598]
51. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol*. 2000; 182:311–322. doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9. [PubMed: 10653597]
52. Qin R, et al. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1alpha pathway to predict survival in resectable pancreatic cancer. *British journal of cancer*. 2015; 112:514–522. doi:10.1038/bjc.2014.659. [PubMed: 25584484]

Figure 1. Co-culture of PANC-1 and Capan-1 cells with PSCs in 2-D monolayer settings
 PDAC cells were labeled with CellTracker CMFDA Green™ before being co-cultured with unlabeled PSCs. Brightfield, FITC fluorescence and color picro-sirius red images of Panc-1 cells alone, Capan-1 cells alone, PSCs alone, PANC-1 and PSCs (co-cultured in 2:1 ratio) and Capan-1 and PSCs (co-cultured in 2:1 ratio) (Scale bars = 1000μm)

Figure 2. Proteomic analysis of PDAC/PSCs interaction

A) Hierarchical clustering of RPPA data of (left panel) PSC in PANC-1 media versus untreated PCSs and (right panel) PANC-1 in PSC media versus untreated PANC-1 (differentially expressed proteins, t test $P < 0.05$, fold change exceeding 1.25 times). B) Activated stroma related pathways enriched by the core-culture signatures. Data are displayed as the $-\log$ of the P value for each pathway.

Figure 3. Brightfield microscopy characterization of micro-tumors co-cultured with and without PSCs

A) Brightfield images of PANC-1, AsPc-1, MIA PaCa-2, Capan-1 and BxPc-3 tumors at 7-day time-point. (White scale bar = 1000μm and red scale bar = 500μm) B) Diameter of PDAC spheroids with and without PSCs at 10-day time-point. C) Optical density of PDAC spheroids with and without PSCs at 10-day time-point (p<0.01). D) Schematic representing the increase in density of tumor due to collagen fibers and PSCs packing regions between PDAC cells.

Figure 4. Scanning electron microscopy of tumor surface

Scanning electron micrograph of A) PANC-1 spheroid B) Capan-1 spheroid, C) PANC-1 PDAC-SS, D) Capan-1 PDAC-SS and E) Orthotopic PDAC tumor from mouse model.

Figure 5. Collagen content of PDAC tumors

A) Picro Sirius staining of various PDAC spheroids with and without PSCs, B)

Quantification of collagen positive regions per unit area of tumor. (white and red scale bars= 500 μ m and yellow scale bars = 200 μ m *p<0.05).

Figure 6. Staining of the stroma fibrosis

Immunohistochemistry of PDAC stroma collagen components in PDAC-SS, as compared to orthotopic PDAC mouse tumors and human grade 2 stage 1 PDAC. Tissues sections stained for collagen 1, collagen 3, and fibronectin and smooth muscle actin (SMA) (Black scale bars = 500µm, red scale bars = 200µm).

Figure 7. Diffusion of molecules through PANC-1 spheroids with and without PSCs
 FITC fluorescent molecule (MW=389.382 g/mol) was used as a model for gemcitabine (MW=263.198 g/mol) to visualize the diffusion through PANC-1 spheroids with and without PSCs. (A) FITC fluorescent images of PANC-1 spheroid regions with and without PSCs/ collagen component B) quantification of the fluorescent intensity per unit area of spheroid after 24h of FIT exposure ($p < 0.05$) and C) Cross-sectional FITC fluorescence from spheroid border through to spheroid centre (lower inset images display typical position of intensity measurement across centre of spheroid) D) LC-MS quantification of gemcitabine content normalized to spheroid surface area (spheroid assumed to be perfectly spherical during normalization) in PANC-1 spheroids with and without PSCs (Scale bars = 300 μ m, * indicates $p < 0.05$).

Figure 8.

Histological analysis after 24h exposure of gemcitabine. Structural integrity and of PDAC spheroids with and without PSCs after 24h gemcitabine exposure. A) Color images of H&E stained histological slides show (left) zoomed representative image of a PANC1 spheroid without PSCs and (right) a PANC1 spheroid with PSCs after 24h gemcitabine exposure. B) Quantification of circularity and solidity of PANC-1 spheroids with and without PSCs. (scale bars = 1000 μ m, $p < 0.01$) (Robustness of segmentation algorithm is shown in Figure S7). * $p < 0.05$.

Figure 9. Histological analysis after 120h exposure of gemcitabine. Proliferative index, measured by Ki67 staining, of PDAC spheroids with and without PSCs after 120h gemcitabine exposure. Color images of Ki67 stained histological slides show (left) PANC1 spheroids without PSCs and (right) PANC1 spheroids with PSCs after 0h (top row) and 120h (bottom row) gemcitabine exposure.

Table 1

Donor patient information and cell line characteristics

Cell line	Source	Derivation	Metastasis	Proliferation	Differentiation	Ref.
PANC-1	56 y.o, female	Primary tumor	Yes	52h	Poor	24
AsPc-1	62 y.o, female	Ascites	Yes	38-40h	Poor	25
MIA PaCa-2	65 y.o, female	Primary tumor	Not described	40h	Poor	26
Capan-1	40 y.o, male	Liver metastasis	Yes	Not described	Well	27
BxPc-3	61 y.o, male	Primary tumor	No	48-60h	Moderate to poor	28